The Cancer Letter

Inside information on cancer research and drug development

The MD Anderson 2014 BIG Survey: In Their Own Words

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In Their Own Words

These comments by MD Anderson faculty and staff members were selected from an 835-page document. They appear exactly as they were keyed in, with no editing. The document was obtained under the Texas Public Information Act. Names and titles of MD Anderson officials were redacted.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
By McKenzie Prillaman

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account